A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.


Journal

Canadian Urological Association journal = Journal de l'Association des urologues du Canada
ISSN: 1911-6470
Titre abrégé: Can Urol Assoc J
Pays: Canada
ID NLM: 101312644

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 1 2 2022
medline: 1 2 2022
entrez: 31 1 2022
Statut: ppublish

Résumé

We aimed to investigate several clinical and biochemical parameters, including palliative external beam radiation therapy (EBRT) to predict survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 ( We tested known and possible prognostic parameters, including palliative EBRT, both prior and concurrent to A total of 133 patients were treated with We found that

Identifiants

pubmed: 35099384
pii: cuaj.7591
doi: 10.5489/cuaj.7591
pmc: PMC9245955
doi:

Types de publication

Journal Article

Langues

eng

Pagination

199-205

Références

Lancet Oncol. 2016 Sep;17(9):1306-16
pubmed: 27473888
Ann Nucl Med. 2018 Feb;32(2):142-148
pubmed: 29285670
Clin Genitourin Cancer. 2020 Aug;18(4):284-294
pubmed: 32057714
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Lancet Oncol. 2014 Jun;15(7):738-46
pubmed: 24836273
Ann Oncol. 2017 May 1;28(5):1090-1097
pubmed: 28453701
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
BMC Cancer. 2019 Jan 7;19(1):12
pubmed: 30612558
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Ann Nucl Med. 2020 Oct;34(10):772-780
pubmed: 32654030
Clin Genitourin Cancer. 2017 Dec;15(6):e969-e975
pubmed: 28545997
Neoplasma. 2013;60(3):328-33
pubmed: 23374004
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
Clin Genitourin Cancer. 2019 Oct;17(5):348-355.e5
pubmed: 31311763
Eur Urol. 2018 Mar;73(3):427-435
pubmed: 28705540
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20
pubmed: 26416392
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Clin Oncol (R Coll Radiol). 2018 Sep;30(9):548-555
pubmed: 29934104
Int J Clin Oncol. 2021 Jan;26(1):192-198
pubmed: 32875513

Auteurs

Cédric Charrois-Durand (C)

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Fred Saad (F)

Division of Urology, Department of Surgery, CHUM, Montreal, QC, Canada.

Maroie Barkati (M)

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Jean-Baptiste Lattouf (JB)

Division of Urology, Department of Surgery, CHUM, Montreal, QC, Canada.

Paul Perrotte (P)

Division of Urology, Department of Surgery, CHUM, Montreal, QC, Canada.

Pierre I Karakiewicz (PI)

Division of Urology, Department of Surgery, CHUM, Montreal, QC, Canada.

Denis Soulières (D)

Department of Hemato-Oncology, CHUM, Montreal, QC, Canada.

Normand Blais (N)

Department of Hemato-Oncology, CHUM, Montreal, QC, Canada.

Zineb Hamilou (Z)

Department of Hemato-Oncology, CHUM, Montreal, QC, Canada.

Daniel Juneau (D)

Department of Nuclear Medicine, CHUM, Montreal, QC, Canada.

Nicolas Plouznikoff (N)

Department of Nuclear Medicine, CHUM, Montreal, QC, Canada.

Daniel Taussky (D)

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Guila Delouya (G)

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.

Classifications MeSH